# A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unres

Source: https://onco.cc/trials/nct07291076/  
OnCo record `nct07291076` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PM8002, Ipilimumab in hepatocellular carcinoma, run by Bristol-Myers Squibb, now recruiting.

## Summary

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) is a phase 1/2 interventional study registered as NCT07291076 by Bristol-Myers Squibb, with 198 participants planned, started 2026-03-16 and due to reach its primary completion in 2029-10-15. Interventions recorded: Pumitamig, Ipilimumab. Conditions listed: Hepatocellular Carcinoma (HCC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07291076
- Phase: 1/2
- Setting: ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
- Sponsor: Bristol-Myers Squibb
- Enrolled: 198

## Sources

- ClinicalTrials.gov NCT07291076: https://clinicaltrials.gov/study/NCT07291076

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct07291076.json